Overview Fundamentals API Earnings EOD API Sample Code Pricing

RenovoRx Inc (RNXT NASDAQ) stock market data APIs

$1.2 -0.04(-3.2%) as of July 23, 2024
Price chart is built with Anychart

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx Inc Financial Data Overview

29 700 K
23 952 K
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RNXT',
Type: 'Common Stock',
Name: 'RenovoRx Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG005XWWZK6',
CIK: '1574094',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-08-26',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,

RenovoRx Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -11 390 000
  • Earnings Per Share -0.7
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get RenovoRx Inc Earnings via APIs

  • Latest Release 2024-05-10
  • EPS/Forecast -0.14

Get RenovoRx Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?